Perspective Piece

Yaws: 110 Years After Castellani's Discovery of *Treponema pallidum* subspecies *pertenue*

Lola V. Stamm*

Department of Epidemiology, Program in Infectious Diseases, Michael Hooker Research Center, University of North Carolina at Chapel Hill, Gillings School of Global Public Health, Chapel Hill, North Carolina

Abstract. Yaws is a neglected infectious disease that affects mostly children and adolescents living in poor, rural communities in humid, tropical areas of Africa, southeast Asia, and the Pacific Islands. The etiological agent of yaws, *Treponema pallidum* subspecies *pertenue* (*T. pertenue*), was discovered by Aldo Castellani in 1905 shortly after Schaudinn and Hoffmann discovered the etiological agent of syphilis, *T. pallidum* subspecies *pallidum*. The discovery of *T. pertenue* enabled the development of animal models and the identification of an effective antibiotic treatment (i.e., penicillin) for yaws. A World Health Organization (WHO) mass treatment campaign from 1952 to 1964 reduced the global burden of yaws by 95%, but failed to eradicate this disease. Today, 110 years after Castellani's discovery of *T. pertenue*, yaws is again targeted for eradication. Recent advances in the treatment and diagnosis of yaws improve the likelihood of success this time. However, several challenges must be overcome to make the goal of yaws eradication attainable.

Yaws is an infectious disease that affects mostly children and adolescents, aged 2–15 years, who live in poor, rural communities in humid, tropical areas of Africa, southeast Asia, and the Pacific Islands.¹ Yaws is currently thought to be endemic in at least 12 countries, but adequate surveillance data are lacking.² This disease is transmitted by contact of broken or abraded skin with the exudate of yaws lesions. Clinical manifestations of yaws are divided into stages. Early stage skin lesions are infectious and can persist for weeks or months. Involvement of the bones of the upper and lower limbs and the fingers and toes can cause pain and digital swelling. After the early stage lesions subside due to the host immune response, the patient enters a latent stage that can be lifelong. In about 10% of untreated patients, the infection progresses to the tertiary stage that is characterized by destruction of tissue, bone, and cartilage resulting in disfigurement and disability.¹

The etiological agent of yaws, *T. pallidum* subspecies *pertenue* (i.e., *T. pertenue*), was discovered in 1905 by Aldo Castellani, a physician and expert in neglected tropical diseases. Castellani had observed spiral-shaped bacteria in lesion material from yaws patients in Sri Lanka (formerly Ceylon), but did not ascribe significance to this observation. However, after learning of the 1905 discovery of the syphilis agent, *T. pallidum* subspecies *pallidum* (i.e., *T. pallidum*), by Schaudinn and Hoffmann³ and cognizant of the similarities of syphilis and yaws, Castellani examined new scrapings from yaws lesions. Using special staining techniques, he again observed delicate, faintly stained spirochetes that were morphologically indistinguishable from *T. pallidum*. Castellani's preliminary findings were presented to the Ceylon Branch of the British Medical Association in June 1905.⁴ After studying lesion material from additional yaws cases, he proposed "*Spirochaeta pertenue*" (i.e., *T. pertenue*) as the etiological agent of yaws.^{5,6} Castellani's findings were soon confirmed by the December 1905 report of Wellman, who had observed spirochetes in the lesions of an African yaws patient.⁷

The discovery of *T. pertenue* enabled the development of animal models for experimental studies of yaws. Castellani investigated the infectious nature of the noncultivable *T. pertenue* in monkeys.⁸ He showed that 1) monkeys could be experimentally infected with an inoculum prepared from the lesions of yaws patients, 2) the inoculum could be rendered noninfectious by removal of *T. pertenue* by filtration, and 3) yaws could be serially transferred in monkeys, and *T. pertenue* was invariably present in "pure culture" in the monkeys' non-ulcerated lesions. Using a modification of Wassermann's complement fixation test for serodiagnosis of syphilis, Castellani detected antibody reactivity in the sera of yaws-infected monkeys, but not naïve monkeys, to antigen in an extract of yaws lesions.⁸ In addition, Castellani demonstrated that yaws-infected monkeys were not immune to syphilis and, conversely, that syphilis-infected monkeys were not immune to yaws (i.e., there is no cross-protection conferred by infection).⁸ This observation along with the previously published work of Neisser and co-workers,⁹ dispelled the belief that syphilis and yaws were the same disease, but with different clinical manifestations because of host genetics and climate. In 1910, Nichols reported that rabbits could be infected intratesticularly with *T. pertenue* and proposed that these animals could provide a more practicable model of yaws for the investigation of immunity and treatments.¹⁰

Because of the biological similarities of *T. pallidum* and *T. pertenue*, there was optimism that syphilis treatments would be effective for yaws. In 1907, Castellani reported the results of various syphilis treatments on small numbers of yaws patients.¹¹ He noted a dramatic improvement of yaws lesions following administration of mercury by the oral or intramuscular route. However, as observed with syphilis, mercurials alone were not curative because yaws lesions usually reappeared after treatment cessation. In 1910, salvarsan (compound 606), an arsenical developed by Ehrlich in Germany, showed promising results for syphilis treatment.¹² Castellani noted that salvarsan was more effective than mercury for yaws treatment.^{13,14} Strong (1911), Alston (1912), Cockin (1913), and McDonald (1915) reported that one injection of salvarsan, given intravenously or intramuscularly, could cure early and late yaws.^{15–18} The few relapses, or possible reinfections, which occurred were successfully retreated with salvarsan. Interestingly, salvarsan appeared to be more

*Address correspondence to Lola V. Stamm, Department of Epidemiology, Program in Infectious Diseases, 3103 Michael Hooker Research Center, University of North Carolina at Chapel Hill, Gillings School of Global Public Health, S. Columbia Street, Chapel Hill, NC 27599-7435. E-mail: lstamm@email.unc.edu

effective for yaws than it was for syphilis. Nichols postulated that the need for prolonged treatment of syphilis with salvarsan was due to the more invasive nature of *T. pallidum*, which enabled it to survive in body sites where the concentration of salvarsan was subtherapeutic.¹⁹ In 1914, Ehrlich developed neosalvarsan (compound 914), which was easier to administer and had less side effects than salvarsan.¹² Harper²⁰ and Greggio¹⁴ reported that neosalvarsan was effective for yaws treatment. Later, mapharsen, a partially oxidized product of salvarsan, was found to cure syphilis.¹² This arsenical, which was patented in 1937, was less toxic than neosalvarsan and could be given in smaller doses. Longley and co-workers²¹ showed that both mapharsen and neosalvarsan were effective for curing rabbits infected with yaws. However, the use of mapharsen for yaws treatment was limited because arsenicals essentially became obsolete when penicillin became available in the 1940s. Following the 1943 report of Mahoney and co-workers²² on the curative action of penicillin for syphilis, there were multiple reports of small numbers of yaws cases that were cured with penicillin.²³ Dwindelle and co-workers²³ treated 500 Haitian patients in early yaws with penicillin and demonstrated the therapeutic efficacy of this drug, which became the mainstay for the treatment and control of yaws.

Nearly 50 years after Castellani's discovery of *T. pertenue*, a major effort was made to eradicate yaws. From 1952 to 1964, the WHO, in concert with the United Nations Children's Fund (UNICEF), sponsored a mass treatment campaign in 46 countries.^{1,2,24} About 300 million people were screened and 50 million or more cases and their contacts were treated with an intramuscular injection of long-acting penicillin. By the end of this campaign, the global burden of yaws was reduced by 95% to 2.5 million cases. Unfortunately, the lack of sustained surveillance and the waning of commitment and resources resulted in the reemergence of yaws in Africa, Asia, and the Pacific in the late 1970s. Although control activities were renewed in several countries and efforts were made to galvanize support from the international community, yaws eradication failed.

Today, 110 years after the discovery of *T. pertenue*, yaws is again targeted for eradication. The WHO's "Morges strategy" for yaws eradication by 2020 is based on mass treatment of individuals in endemic communities followed by clinical and serological surveys at 6-month intervals to detect and treat the remaining cases and their contacts.^{24,25} Two recent advances for treatment and diagnosis of yaws should greatly aid eradication efforts. First, Mitja and others showed in two separate studies conducted in Papua New Guinea that a single, oral dose of azithromycin (30 mg/kg body weight; maximum dose of 2 g) is as effective as intramuscular benzathine penicillin (1.2 million units (MU) for adults, 0.6 MU for children) for yaws treatment and is more feasible to administer in the field.^{26,27} Azithromycin, which has recently replaced penicillin as the WHO-preferred drug for yaws, will be used for mass treatment in communities where yaws is endemic. Second, Ayove and others²⁸ showed that a point-of-care serological test for syphilis diagnosis, the Dual Path Platform (DPP) Syphilis Screen and Confirm, is sufficiently sensitive and specific for rapid diagnosis of yaws under field conditions using finger-stick blood. This important development obviates the need for venipuncture to obtain serum samples and for transport of serum samples to a distant laboratory for testing. The DPP test will be used to detect yaws cases that are difficult

to diagnose based on clinical symptoms because unrelated bacteria, such as *Haemophilus ducreyi*, can cause phenotypically similar skin lesions.¹ The DPP test may also be used for monitoring the effectiveness of azithromycin treatment.

Undoubtedly, many challenges must be overcome for yaws eradication to succeed. Aside from major financial and commitment issues, several uncertainties related to the biology and epidemiology of yaws could impede this endeavor.^{1,2,29} Because there is no vaccine to prevent infection, antibiotic treatment must be effective to interrupt transmission of yaws. The use of oral azithromycin as the first-line drug, while warranted based on logistics, could result in the emergence of azithromycin-resistant *T. pertenue*, as has been observed with *T. pallidum*.^{30,31} This possibility requires careful monitoring. Furthermore, although the prevalence of yaws is undoubtedly less than it was at the time of the first WHO eradication campaign, the current burden and distribution of yaws are unknown.^{2,24} The inability to find and treat yaws cases, particularly in remote areas of previously endemic countries that have not reported cases to the WHO since 1990, could allow yaws to resurface. Despite these concerns, recent advances in the treatment and diagnosis of yaws and a more favorable climate for control of neglected tropical diseases have renewed hope that yaws eradication can be achieved. What more fitting tribute could there be to Aldo Castellani, the discoverer of *T. pertenue*, than to finally vanquish this "end of the road" disease?

Received February 20, 2015. Accepted for publication March 8, 2015.

Published online April 13, 2015.

Author's address: Lola V. Stamm, Department of Epidemiology, Program in Infectious Diseases, 3103 Michael Hooker Research Center, University of North Carolina at Chapel Hill, Gillings School of Global Public Health, Chapel Hill, NC, E-mail: lstamm@email.unc.edu.

REFERENCES

1. Marks M, Mitja O, Solomon AW, Asiedu KB, Mabey DC, 2014. Yaws. *Brit Med Bull* 113: 91–100.
2. Kazadi WM, Asiedu KB, Agana N, Mitja O, 2014. Epidemiology of yaws: an update. *Clin Epidemiol* 6: 119–128.
3. Thorburn AL, 1971. Fritz Richard Schaudinn, 1871–1906. Protozoologist of syphilis. *Br J Vener Dis* 47: 459–461.
4. Castellani A, 1905. On the presence of spirochaetes in some cases of parangi (yaws, framboesia tropica) preliminary note. *J Ceylon Branch Brit Med Assoc* 2: 54.
5. Castellani A, 1905. Further observations on parangi (yaws). *BMJ* 2: 1330–1331.
6. Castellani A, 1907. Note on the spirochaete of yaws (*Spirochaeta pertenue*). *BMJ* 2: 1511–1512.
7. Wellman FC, 1905. On a spirochaete found in yaws papules. *J Trop Med* 8: 345.
8. Castellani A, 1907. Experimental investigations on framboesia tropica (yaws). *J Hyg (Lond)* 7: 558–569.
9. Neisser A, Baermann G, Halberstadter L, 1906. Researches on the transmission of yaws to monkeys. *Munch Med Wochenschr* 53: 1337–1338.
10. Nichols HJ, 1910. Experimental yaws in the monkey and rabbit. *J Exp Med* 12: 616–621.
11. Castellani A, 1907. Observations on the treatment of yaws (framboesia). *Lancet* 170: 1458–1459.
12. Bosch F, Rosich L, 2008. The contributions of Paul Ehrlich to pharmacology: a tribute on the occasion of the centenary of his Nobel Prize. *Pharmacol* 82: 171–179.
13. Castellani A, 1915. Note on the internal treatment of yaws. *J Trop Med Hyg* 18: 61–63.

14. Greggio G, 1917. Treatment of yaws and other diseases in the Belgian Congo by Neosalvarsan. *Trans R Soc Trop Med Hyg* 10: 189–193.
15. Strong RP, 1911. The treatment of yaws (framboesia) with arsenobenzol (Salvarsan). *J Exp Med* 13: 412–415.
16. Alston H, 1912. Salvarsan in yaws. *BMJ* 1: 14.
17. Cockin RP, 1913. Treatment of yaws by intramuscular injections of Salvarsan. A report on a series of 45 cases treated at the yaws hospital, St. George's, Grenada, BWI. *Lancet* 182: 1609–1610.
18. McDonald WM, 1915. Salvarsan in the treatment of yaws. *Lancet* 186: 649–650.
19. Nichols HJ, 1911. Further observations on certain features of experimental syphilis and yaws in the rabbit. *J Exp Med* 14: 196–216.
20. Harper P, 1914. Treatment of yaws by intravenous and intramuscular injections of salvarsan and neosalvarsan. *Lancet* 184: 370–372.
21. Longley BJ, Clausen NM, Tatum AL, 1941. A comparison of the response of yaws and syphilis in the rabbit to therapy with mapharsen and neoarsphenamine. *J Pharmacol Exp Ther* 71: 49–51.
22. Mahoney JF, Arnold RC, Harris A, 1943. Penicillin treatment of early syphilis—a preliminary report. *Am J Public Health* 33: 1387–1391.
23. Dwindelle JH, Rein CR, Sternberg TH, Sheldon AJ, 1946. Preliminary report on the evaluation of penicillin in the treatment of yaws. *Am J Trop Med Hyg* 26: 311–318.
24. Asiedu K, Fitzpatrick C, Jannin J, 2014. Eradication of yaws: historical efforts and achieving WHO's 2020 target. *PLoS Negl Trop Dis* 8: e3016.
25. The World Health Organization, 2012. Eradication of yaws—the Morges strategy. *Wkly Epidemiol Rec* 87: 189–194.
26. Mitja O, Hays R, Ipai A, Penias M, Paru R, Fagaho D, de Lazzari E, Bassat Q, 2012. Single-dose azithromycin versus benzathine benzylpenicillin for treatment of yaws in children in Papua New Guinea: an open-label, non-inferiority, randomized trial. *Lancet* 379: 342–347.
27. Mitja O, Houine W, Moses P, Kapa A, Paru R, Hays R, Lukehart S, Godornes C, Bieb SV, Grice T, Siba P, Mabey D, Sanz S, Alonso PL, Asiedu K, Bassat Q, 2015. Mass treatment with single-dose azithromycin for yaws. *N Engl J Med* 372: 703–710.
28. Ayove T, Hounie W, Wangnapi R, Bieb SV, Kazadi W, Luke L-N, Manineng C, Moses P, Paru R, Esfandiari J, Alonso PL, de Lazzari E, Bassat Q, Mabey D, Mitja O, 2014. Sensitivity and specificity of a rapid point-of-care test for active yaws: a comparative study. *Lancet Glob Health* 2: e415–e421.
29. Stamm LV, 2014. Yaws: renewed hope for eradication. *JAMA Dermatol* 150: 933–934.
30. Stamm LV, 2015. Syphilis: antibiotic treatment and resistance. *Epidemiol Infect* 143: 1567–1574.
31. Mabey D, 2012. Oral azithromycin for treatment of yaws. *Lancet* 379: 295–296.